USAID ELIMINATING TUBERCULOSIS in CENTRAL ASIA (USAID ETICA) PROJECT Year 1 Annual Report: October 2019 – September 2020
Total Page:16
File Type:pdf, Size:1020Kb
Preparation of buffer solution, National Reference Laboratory, Tashkent, Uzbekistan USAID ELIMINATING TUBERCULOSIS IN CENTRAL ASIA (USAID ETICA) PROJECT Year 1 Annual Report: October 2019 – September 2020 November 10, 2020 DISCLAIMER This report is made possible by the support of the American People through the United States Agency for International Development (USAID). The authors’ views expressed in this publication do not necessarily reflect the views of USAID or the United States Government. Submitted to: Arman Toktabayanov, COR, Regional TB Advisor, Health and Education Office, USAID/Central Asia, Almaty, Kazakhstan. Lola Yuldasheva, Alternate COR, Project Management Specialist/Health, USAID/Tajikistan, Dushanbe Abt Associates Inc. 1 6130 Executive Boulevard 1 Rockville, Maryland 20814 1 T. 301.347.5000 1 www.abtassociates.com With: PATH IML red RPX AFEW Kazakhstan Afif Tajikistan National Red Crescent Society of Tajikistan USAID ETICA: YEAR 1 ANNUAL REPORT: OCTOBER 2019 – SEPTEMBER 2020 | 1 USAID ELIMINATING TUBERCULOSIS IN CENTRAL ASIA (USAID ETICA) PROJECT Year 1 Annual Report: October 2019 – September 2020 Contract No.: 72011519C00002 DISCLAIMER: This report is made possible by the support of the American People through the United States Agency for International Development (USAID). The authors’ views expressed in this publication do not necessarily reflect the views of USAID or the United States Government. USAID ETICA: YEAR 1 ANNUAL REPORT: OCTOBER 2019 – SEPTEMBER 2020 | 2 TABLE OF CONTENTS LIST OF EXHIBITS ....................................................................................................................5 LIST OF ANNEXES ..................................................................................................................6 ACRONYMS AND ABBREVIATIONS.................................................................................7 EXECUTIVE SUMMARY ..........................................................................................................9 KEY ACHIEVEMENTS .......................................................................................................... 10 1. INTRODUCTION ..................................................................................................... 13 1.1 BACKGROUND ................................................................................................................................ 13 1.2 ANNUAL REPORT STRUCTURE ................................................................................................. 13 1.3 STATUS OF DELIVERABLES .......................................................................................................... 13 1.4 PERFORMANCE MONITORING .................................................................................................. 14 1.5 IMPACT OF COVID-19 ON THE IMPLEMENTATION OF USAID ETICA ...................... 15 2. TAJIKISTAN ................................................................................................................. 18 2.1 EXECUTIVE SUMMARY................................................................................................................... 18 2.2 SUMMARY OF STAFFING AND OPERATIONS ...................................................................... 21 2.3 COVID-19 RELATED ACTIVITIES ................................................................................................ 21 2.4 OBJECTIVE 1: INCREASED DETECTION OF TB AND DR-TB .......................................... 22 2.5 OBJECTIVE 2: INCREASED TREATMENT SUCCESS FOR TB AND ALL TYPES OF DR-TB 32 2.6 OBJECTIVE 3: IMPROVED ENABLING ENVIRONMENT AND FINANCIAL SUSTAINABILITY OF TB AND DR-TB PROGRAMS ........................................................................... 36 2.7 PERFORMANCE MONITORING .................................................................................................. 44 2.8 COORDINATION WITH PARTNERS ........................................................................................ 49 2.9 OBSTACLES AND CHALLENGES ................................................................................................ 50 2.10 WAY FORWARD .............................................................................................................................. 50 3. UZBEKISTAN .............................................................................................................. 54 3.1 EXECUTIVE SUMMARY................................................................................................................... 54 3.2 SUMMARY OF STAFFING AND OPERATIONS ...................................................................... 55 3.3 COVID-19 ............................................................................................................................................ 56 3.4 OBJECTIVE 1: INCREASED DETECTION OF TB AND DR-TB .......................................... 56 3.5 OBJECTIVE 2: INCREASED TREATMENT SUCCESS FOR TB AND ALL TYPES OF DR-TB 63 USAID ETICA: YEAR 1 ANNUAL REPORT: OCTOBER 2019 – SEPTEMBER 2020 | 3 3.6 OBJECTIVE 3: IMPROVED ENABLING ENVIRONMENT AND FINANCIAL SUSTAINABILITY OF TB AND DR-TB PROGRAMS ........................................................................... 66 3.7 COVID-19 RELATED RISKS AND CHALLENGES ................................................................... 67 3.8 PERFORMANCE MONITORING .................................................................................................. 67 3.9 COORDINATION WITH PARTNERS ........................................................................................ 70 3.10 OBSTACLES AND CHALLENGES ................................................................................................ 70 3.11 WAY FORWARD .............................................................................................................................. 71 4. KAZAKHSTAN ........................................................................................................... 73 4.1 EXECUTIVE SUMMARY................................................................................................................... 73 4.2 SUMMARY OF STAFFING AND OPERATIONS ...................................................................... 76 4.3 OBJECTIVE 1: INCREASED DETECTION OF TB AND DR-TB .......................................... 77 4.4 OBJECTIVE 2: INCREASED TREATMENT SUCCESS FOR TB AND ALL TYPES OF DR-TB 83 4.5 OBECTIVE 3: IMPROVED ENABLING ENVIRONMENT AND FINANCIAL SUSTAINABILITY OF TB AND DR-TB PROGRAMS ........................................................................... 87 4.6 COVID-19 RELATED ACTIVITIES ................................................................................................ 90 4.7 COVID-19 RELATED RISKS AND CHALLENGES ................................................................... 90 4.8 PERFORMANCE MONITORING .................................................................................................. 91 4.9 COORDINATION WITH PARTNERS ........................................................................................ 93 4.10 OBSTACLES AND CHALLENGES ................................................................................................ 93 4.11 WAY FORWARD .............................................................................................................................. 94 5. GENDER ORIENTATION IN PROJECT .............................................................. 97 5.1 PROJECT GENDER INTEGRATION STRATEGY .................................................................... 98 5.2 PROJECT ACHIEVEMENTS ON GENDER INTEGRATION ................................................. 99 5.3 SUSTAINABILITY IN GENDER APPROACHES ......................................................................101 6. PERFORMANCE MONITORING ........................................................................ 102 BASELINE ASSESSMENT ............................................................................................................................102 ASSESSMENT OF STIGMA, GENDER, AND OTHER SOCIAL BARRIERS TO TB DETECTION AND TREATMENT ......................................................................................................................................103 6.2 MONITORING, EVALUATION, AND LEARNING PLAN ..................................................103 7. BUDGET EXPENDITURES ........ ERROR! BOOKMARK NOT DEFINED. USAID ETICA: YEAR 1 ANNUAL REPORT: OCTOBER 2019 – SEPTEMBER 2020 | 4 LIST OF EXHIBITS Exhibit 1. Trained personnel in Y1 ........................................................................................................................ 21 Exhibit 2. Diagnostic Algorithm.............................................................................................................................. 27 Exhibit 3. Analysis of BDQ resistance research ................................................................................................. 31 Exhibit 4. Digitalization of TB Continuum of care in Tajikistan ..................................................................... 39 Exhibit 5. Gender disaggregation in the indicators in pilot regions ............................................................... 45 Exhibit 6. Achievement of targets, Tajikistan ...................................................................................................... 46 Exhibit 7. Online monitoring process ..................................................................................................................